"id","rationale","versionIdentifier","uuid:ID","instanceType"
"StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","51907b2d-7d3d-4141-90e4-fff514e9044e","StudyVersion"
